Conservative treatment of endometrial cancer in women of reproductive age (Review).

IF 1.4 Q4 ONCOLOGY
Maria Zoi Bourou, Alkis Matsas, Thomas Vrekoussis, Georgios Mastorakos, Georgios Valsamakis, Theodoros Panoskaltsis
{"title":"Conservative treatment of endometrial cancer in women of reproductive age (Review).","authors":"Maria Zoi Bourou,&nbsp;Alkis Matsas,&nbsp;Thomas Vrekoussis,&nbsp;Georgios Mastorakos,&nbsp;Georgios Valsamakis,&nbsp;Theodoros Panoskaltsis","doi":"10.3892/mco.2023.2651","DOIUrl":null,"url":null,"abstract":"<p><p>Endometrial cancer is the fifth most common female cancer worldwide and the third leading female cancer in the Western world. The marked surge in endometrial cancer incidence is alarming. The aim of the present review is to focus on endometrial cancer affecting young women of reproductive age. Surgery, namely abdominal or laparoscopic hysterectomy, with or without salpingo-oophorectomy, and sentinel lymph node detection has become the standard surgical strategy for early stage endometrioid endometrial cancer. However, premenopausal women might want to preserve their fertility, especially if they are nulliparous or have not reached their desired number of children at the time of diagnosis. Conservative, uterus-sparing treatment, based on progestin products, may be an advantageous option for patients meeting the necessary criteria. Potential candidates have to be committed to following a rigorous protocol of treatment, investigations and follow-up. The evidence in favor of this approach, although limited, is encouraging and patients who have achieved a histologically documented disease complete remission could attempt to conceive spontaneously or with the immediate use of assisted reproductive technology techniques. The risk of partial or negative response to progestin treatment or cancer recurrence is well documented, thus patients have to be aware of the possible need for interruption of conservative treatment and hysterectomy.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 1","pages":"55"},"PeriodicalIF":1.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/59/mco-19-01-02651.PMC10265581.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/mco.2023.2651","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Endometrial cancer is the fifth most common female cancer worldwide and the third leading female cancer in the Western world. The marked surge in endometrial cancer incidence is alarming. The aim of the present review is to focus on endometrial cancer affecting young women of reproductive age. Surgery, namely abdominal or laparoscopic hysterectomy, with or without salpingo-oophorectomy, and sentinel lymph node detection has become the standard surgical strategy for early stage endometrioid endometrial cancer. However, premenopausal women might want to preserve their fertility, especially if they are nulliparous or have not reached their desired number of children at the time of diagnosis. Conservative, uterus-sparing treatment, based on progestin products, may be an advantageous option for patients meeting the necessary criteria. Potential candidates have to be committed to following a rigorous protocol of treatment, investigations and follow-up. The evidence in favor of this approach, although limited, is encouraging and patients who have achieved a histologically documented disease complete remission could attempt to conceive spontaneously or with the immediate use of assisted reproductive technology techniques. The risk of partial or negative response to progestin treatment or cancer recurrence is well documented, thus patients have to be aware of the possible need for interruption of conservative treatment and hysterectomy.

Abstract Image

育龄妇女子宫内膜癌的保守治疗(综述)。
子宫内膜癌是世界上第五大最常见的女性癌症,也是西方世界第三大女性癌症。子宫内膜癌发病率的显著上升令人担忧。本综述的目的是关注影响育龄年轻妇女的子宫内膜癌。手术,即腹腔或腹腔镜子宫切除术,合并或不合并输卵管-卵巢切除术,前哨淋巴结检测已成为早期子宫内膜样子宫内膜癌的标准手术策略。然而,绝经前妇女可能想要保持她们的生育能力,特别是如果她们在诊断时没有生育或没有达到她们期望的孩子数量。保守的,保留子宫的治疗,基于黄体酮产品,可能是一个有利的选择,患者符合必要的标准。潜在的候选人必须遵守严格的治疗、调查和随访协议。支持这种方法的证据虽然有限,但令人鼓舞,组织学证明疾病完全缓解的患者可以尝试自发怀孕或立即使用辅助生殖技术。对黄体酮治疗的部分或负面反应或癌症复发的风险是有充分记录的,因此患者必须意识到可能需要中断保守治疗和子宫切除术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
108
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信